Cell Metab:白血病、炎症治疗的新策略

2015-01-09 佚名 生物谷

根据华盛顿大学医学院一项新的研究证实:与糖尿病和肥胖相关的酶可能在关节炎和白血病中发挥关键作用,这就有可能开辟治疗这些疾病的新途径。 利用遗传工程小鼠开展的研究工作,研究人员发现参与将碳水化合物转化为脂肪的酶也影响特定白细胞即中性粒细胞的健康。嗜中性粒细胞是最丰富的类型的白血细胞,其是炎症的标志,而炎症是类风湿关节炎的一个关键组成部分。异常高水平的中性粒细胞在白血病患者也常见。 这项研究发表在

根据华盛顿大学医学院一项新的研究证实:与糖尿病和肥胖相关的酶可能在关节炎和白血病中发挥关键作用,这就有可能开辟治疗这些疾病的新途径。

利用遗传工程小鼠开展的研究工作,研究人员发现参与将碳水化合物转化为脂肪的酶也影响特定白细胞即中性粒细胞的健康。嗜中性粒细胞是最丰富的类型的白血细胞,其是炎症的标志,而炎症是类风湿关节炎的一个关键组成部分。异常高水平的中性粒细胞在白血病患者也常见。

这项研究发表在Cell Metabolism杂志上。这些酶和中性粒细胞之间的联系是一个巨大的惊喜,论文第一作者Irfan J. Lodhi博士说:我们从来没有想过通过瞄准产生脂肪酸的酶,来治疗类风湿关节炎或白血病。

在这项研究中,小鼠剔除产生某种类型脂肪所需要酶后,小鼠体重突然降低,并含有极低的白细胞数量,极少数的中性粒细胞。如果没有这个脂肪即醚脂,中性粒细胞会死亡。

该发现提示靶向醚脂,或可降低炎性疾病和白血病嗜中性粒细胞的数量。研究人员认为限制,而不是消除醚脂可能是最好的方法,因为嗜中性粒细胞对于抗感染是重要的。

研究员Clay F. Semenkovich医学博士表示:这可能是限制炎症的一个途径,如果我们能降低这些酶的活性,而不完全消除它们,就可能降低醚脂水平,潜在帮助白血病和炎性疾病患者如关节炎。

Semenkovich说,这些酶特异性地靶向中性粒细胞,而不影响其他的免疫细胞。因此,醚脂似乎是一个非常精确的靶标。研究人员还发现失活这些酶不会损伤中性粒细胞的前体细胞,而只杀死成熟中性粒细胞。这意味着限制醚脂生成的策略有可能只是短暂地降低中性粒细胞水平,因此当治疗终止时,患者的粒细胞数量将逐渐升高,使得免疫系统恢复正常。

原始出处

Lodhi IJ1, Wei X1, Yin L1, Feng C1, Adak S1, Abou-Ezzi G2, Hsu FF1, Link DC2, Semenkovich CF3.Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability.Cell Metab. 2015 Jan 6;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-10-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-12-12 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-03-20 guojianrong
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959240, encodeId=f28619592409d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Oct 10 07:19:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895766, encodeId=5cb91895e663b, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Dec 12 11:19:00 CST 2015, time=2015-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868989, encodeId=a2d61868989f7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jun 23 17:19:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887413, encodeId=2316188e41327, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Mar 20 15:19:00 CST 2015, time=2015-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005134, encodeId=c195200513483, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Sat Jan 17 17:19:00 CST 2015, time=2015-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478351, encodeId=a60914e8351f0, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 11 00:19:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]

相关资讯

ASH 2014:Imbruvica使携带del17p突变的CLL患者获益

2014年第56届美国血液学会年会(ASH)于12月6日-9日在美国旧金山举行。会上公布了抗癌药Imbruvica(ibrutinib)II期RESONATE-17(PCYC-1117)研究的数据。研究中,144例携带del17p突变的复发性/难治性慢性淋巴细胞白血病">白血病(CLL,n=133)患者和小细胞淋巴瘤(SLL,n=7)患者接受每日一次Imbruvica单药治疗,直至病情进展。

FDA批准安进高价罕见白血病新药Blincyto

安进公司最新批准的Blincyto用于治疗一种罕见形式的白血病,包括两个循环的疗程,费用高达17.8万美元,使之成为市场上最昂贵的药品之一。 这次高额的价格标签可能会再次引发有关健康体系能否能负担得起孤儿疾病患者的治疗,尤其是有特定患者群体的癌症领域,近年来在市场上出现新的免疫疗法,都达到了10万美元以上的定价。 安进公司的Blincyto(blinatumomab)在本月初获得来自FDA的批

The lancet oncology:白血病治疗的曙光!blinatumomab试验效果乐观

通常,患有复发或顽固性前体B细胞急性淋巴细胞白血病的成年人的预后很差。Blinatumomab是一种双特异性单链抗体,能够靶向CD19和CD3分子。通过引导人体自身的杀伤性T细胞攻击肿瘤细胞,并能够在低浓度下起作用。研究人员尝试验证该药对于治疗急性淋巴细胞白血病的有效性及其药品安全性,开展了一项多中心的,单臂(无对照)的开放性II期临床试验,该结果发表于2014年12月的Lancet Oncolo

Oncology Nursing Forum:急性淋巴细胞白血病患儿及其母亲睡眠质量堪忧

近日,Ellyn Matthews博士发表了关于白血病">急性淋巴细胞白血病(ALL)儿童和他们母亲的睡眠的研究成果。 这项题目名为“Sleep in Mother and Child Dyads During Treatment for Pediatric Acute Lymphoblastic Leukemia”的研究发表在杂志Oncology Nursing Forum上。 研究作

2014 年血液系统恶性肿瘤研究进展大盘点

2014 年即将结束,在过去的一年血液系统恶性肿瘤有哪些研究进展呢?MEDSCAPE 邀请重量级专家对此进行了盘点,包括疾病诊疗及新药进展等方面。 多发性骨髓瘤(MM) 最近,国际多发性骨髓瘤工作组更新了 MM 的最新定义, 这将对临床产生重大影响。诊断 MM 除了必须要有 CRAB 症状(高钙血症、肾衰竭、贫血和骨质破坏),该定义还包括了可以预测早期 CRAB 症状的标记物。 过去我们

Nature:T细胞疗法可延长白血病患者生存期?

当免疫学家Michel Sadelain在2007年时首次对一种经过基因工程改良的抗癌性T细胞进行试验时,他努力寻找着愿意参与该试验的患者。他所提出的治疗方案是:从肿瘤患者体内分离一些T细胞,利用基因工程技术对其进行改良,使其具有肿瘤识别能力,随后再将T细胞注射回患者体内;小鼠研究已经表明这种治疗方法具有可行性。但是Sadelain并没有因为同事拒绝提供患者而迁怒于他们。他说:“